Yahoo Web Search

  1. BIIB, a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2018 results on Apr 24, before the market opens. Last quarter, the company delivered a ...

  2. How Biogen approached a potential AveXis deal will be important to investors come its earnings, scheduled for early Tuesday, said Mizuho analyst...

  3. Email This Story Send this story to: ** Enter the e-mail address of the recipient. Separate multiple addresses with commas. Add your own personal message. Enter your e-mail address: ** ** denotes ...

  4. LOS ANGELES, April 23, 2018 /PRNewswire-USNewswire/ -- Steven L. Galetta, MD, the Philip K. Moskowitz, MD Professor and Chair of Neurology at NYU Langone Health, has been awarded the 2018 A.B ...

  5. "Our work is based on the prediction that disease-specific regulatory elements will be concentrated in the risk loci of complex genetic diseases," said Dr. John B. Harley of the University of Cincinnati, Ohio.

  6. You've had multiple sclerosis for a while now and tried a bunch of things to ease your pain or control those muscle spasms. Is it time, you wonder, to pay attention to all the ...

  7. Exposure to a toxin primarily found in sheep could be linked to the development of multiple sclerosis (MS) in humans, new research suggests. Carried out by the University of Exeter ...

  8. Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. News: Johnson & Johnson (JNJ) recently announced that ...

  9. ... issuer is solely responsible for the content of this announcement. - Analyses of the EXPAND study showed that siponimod (BAF312) reduced the risk of disability progression largely disassociated from relapses in patients with secondary progressive multiple sclerosis (SPMS)[1] - In EXPAND, siponimod also had a meaningful benefit on patients' cognitive processing speed[2] - Findings add to...

  10. With specialty pharmacy spend continuing to grow over the next few years and several potential cost drivers on the horizon including treatments for anti-migraine, oncology and multiple

  1. 12345345 results